164 related articles for article (PubMed ID: 31900910)
1. The Bone Microenvironment in Prostate Cancer Metastasis.
DiNatale A; Fatatis A
Adv Exp Med Biol; 2019; 1210():171-184. PubMed ID: 31900910
[TBL] [Abstract][Full Text] [Related]
2. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
[TBL] [Abstract][Full Text] [Related]
3. Bone-targeting agents in prostate cancer.
Suzman DL; Boikos SA; Carducci MA
Cancer Metastasis Rev; 2014 Sep; 33(2-3):619-28. PubMed ID: 24398856
[TBL] [Abstract][Full Text] [Related]
4. Rat Prostate Tumor Cells Progress in the Bone Microenvironment to a Highly Aggressive Phenotype.
Bergström SH; Rudolfsson SH; Bergh A
Neoplasia; 2016 Mar; 18(3):152-61. PubMed ID: 26992916
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.
Msaouel P; Nandikolla G; Pneumaticos SG; Koutsilieris M
Expert Opin Investig Drugs; 2013 Nov; 22(11):1385-400. PubMed ID: 24024652
[TBL] [Abstract][Full Text] [Related]
7. Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton.
Bogdanos J; Karamanolakis D; Tenta R; Tsintavis A; Milathianakis C; Mitsiades C; Koutsilieris M
Endocr Relat Cancer; 2003 Jun; 10(2):279-89. PubMed ID: 12790789
[TBL] [Abstract][Full Text] [Related]
8. Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer.
Zhang X
Cancer Commun (Lond); 2019 Nov; 39(1):76. PubMed ID: 31753020
[TBL] [Abstract][Full Text] [Related]
9. Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment.
Arnold RS; Fedewa SA; Goodman M; Osunkoya AO; Kissick HT; Morrissey C; True LD; Petros JA
Bone; 2015 Sep; 78():81-6. PubMed ID: 25952970
[TBL] [Abstract][Full Text] [Related]
10. Androgens and prostate cancer bone metastases: effects on both the seed and the soil.
Yang W; Levine AC
Endocrinol Metab Clin North Am; 2011 Sep; 40(3):643-53, x. PubMed ID: 21889726
[TBL] [Abstract][Full Text] [Related]
11. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells.
Russell MR; Jamieson WL; Dolloff NG; Fatatis A
Oncogene; 2009 Jan; 28(3):412-21. PubMed ID: 18850002
[TBL] [Abstract][Full Text] [Related]
12. Recent developments in treatments targeting castration-resistant prostate cancer bone metastases.
Loriot Y; Massard C; Fizazi K
Ann Oncol; 2012 May; 23(5):1085-1094. PubMed ID: 22267211
[TBL] [Abstract][Full Text] [Related]
13. Bone microenvironment signaling of cancer stem cells as a therapeutic target in metastatic prostate cancer.
Lee CH; Decker AM; Cackowski FC; Taichman RS
Cell Biol Toxicol; 2020 Apr; 36(2):115-130. PubMed ID: 31250347
[TBL] [Abstract][Full Text] [Related]
14. Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer.
Chen WY; Tsai YC; Yeh HL; Suau F; Jiang KC; Shao AN; Huang J; Liu YN
Sci Signal; 2017 Aug; 10(492):. PubMed ID: 28811384
[TBL] [Abstract][Full Text] [Related]
15. Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis.
Park SH; Keller ET; Shiozawa Y
Calcif Tissue Int; 2018 Feb; 102(2):152-162. PubMed ID: 29094177
[TBL] [Abstract][Full Text] [Related]
16. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
[TBL] [Abstract][Full Text] [Related]
17. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
18. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
Chung LW; Baseman A; Assikis V; Zhau HE
J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
[TBL] [Abstract][Full Text] [Related]
19. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Divers CH; Valderrama A; Freedland SJ
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):380-384. PubMed ID: 27377207
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer.
Koo KC; Park SU; Kim KH; Rha KH; Hong SJ; Yang SC; Chung BH
Yonsei Med J; 2015 Sep; 56(5):1206-12. PubMed ID: 26256961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
